Comparison of Age-related Macular Degeneration Treatment Trials (CATT)

Age-related Macular Degeneration

National Eye Institute (NEI)

Ivana Kim, M.D.

CATT is a Phase III multi-center, masked, randomized clinical trial.

To determine if it an investigational medication called Avastin works as well or better than an approved medication for neovascular AMD, called Lucentis. Additionally, the study will evaluate how often treatment needs to be given, every month or less often. 

Patients with exudative (or wet) AMD

Qualified participants were randomly assigned to receive Avastin or Lucentis on a monthly or “as needed” basis over a two-year period. Preliminary studies of Avastin suggest that it may help prevent the progression of neovascular AMD. Lucentis has been proven to prevent the progression of neovascular AMD in the majority of patients who receive it.

Edward Miretsky, Study Coordinator

617-573-4382